Bio-Path Holdings
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us
March 16, 2023

Bio-Path Holdings Provides Clinical and Operational Update

December 7, 2022

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid Tumors

November 15, 2022

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS

Some patients reported taking their medication with calcium supplements, calcium-fortified juice, or along with iron supplements.
Buy Synthroid no Prescription Over The Counter The only side effects of Armor is Hypo or Hyper if you take too much or not enough. Tetracycline prevents growth of bacteria by preventing the bacteria from manufacturing proteins that they need to survive. Where to buy Tetracycline 250mg (Sumycin) Online Swallow the tablets when standing or sitting down, do not take them immediately before going to bed.
November 8, 2022

Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022

November 7, 2022

Bio-Path Holdings Announces $2.0 Million Registered Direct Offering and Concurrent Private Placement

October 24, 2022

Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Study of BP1002 in refractory/Relapsed Acute Myeloid Leukemia Patients

September 6, 2022

Bio-Path Holdings to Present at H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS

August 9, 2022

Bio-Path Holdings to Announce Second Quarter 2022 Financial Results on August 16, 2022

Load More
May 17, 2022

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2022 FINANCIAL RESULTS

May 10, 2022

Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022

April 12, 2022

Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual Meeting

April 6, 2022

Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

March 11, 2022

Bio-Path Holdings Reports Full Year 2021 Financial Results

March 8, 2022

Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting

March 4, 2022

Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022

January 5, 2022

Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

December 13, 2021

Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting

November 12, 2021

Bio-Path Holdings Reports Third Quarter 2021 Financial Results

November 5, 2021

Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021

November 4, 2021

Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting

October 27, 2021

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for Phase 1/1b Clinical Trial of Prexigebersen-A in Solid Tumors

August 24, 2021

Bio-Path Holdings Announces Clearance of Investigational New Drug Application for BP1002 in Refractory/Relapsed Acute Myeloid Leukemia Patients

August 13, 2021

Bio-Path Holdings Reports Second Quarter 2021 Financial Results

August 6, 2021

Bio-Path Holdings to Announce Second Quarter 2021 Financial Results on August 13, 2021

June 22, 2021

Bio-Path Granted Key Mechanism of Action U.S. Patent for BP1003

May 14, 2021

Bio-Path Holdings Reports First Quarter 2021 Financial Results

May 7, 2021

Bio-Path Holdings to Announce First Quarter 2021 Financial Results on May 14, 2021

April 22, 2021

Bio-Path Announces Publication in Biomedicines

April 12, 2021

Bio-Path Holdings Presents BP1002 Data at 2021 American Association for Cancer Research Annual Meeting

April 5, 2021

Bio-Path Holdings Announces Successful Completion of Safety Cohort of Triple Combination of Prexigebersen, Decitabine and Venetoclax in Stage 2 of Phase 2 Clinical Trial in Acute Myeloid Leukemia

March 11, 2021

Bio-Path Holdings to Present at the 2021 American Association for Cancer Research Annual Meeting

March 10, 2021

BIO-PATH HOLDINGS REPORTS FULL YEAR 2020 FINANCIAL RESULTS

March 3, 2021

Bio-Path Holdings to Announce Full Year 2020 Financial Results on March 10, 2021

February 18, 2021

Bio-Path Holdings, Inc. Announces Closing of $13.0 Million Public Offering of Common Stock

February 16, 2021

Bio-Path Holdings, Inc. Announces Pricing of $13.0 Million Public Offering of Common Stock

February 13, 2021

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock

February 10, 2021

Bio-Path Receives Third U.S. Patent Grant Related to Manufacture of Platform Technology

November 19, 2020

Bio-Path Holdings Announces First Patient Dosed in Phase 1 Clinical Trial of BP1002

November 13, 2020

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS

November 6, 2020

Bio-Path Holdings to Announce Third Quarter 2020 Financial Results on November 13, 2020

October 22, 2020

Bio-Path Receives Notice of Allowance for Strategic Patent for Prexigebersen in Combination with Front Line Cytidine Analogues or Bcr-Abl Tyrosine Kinase Inhibitors in a Variety of Cancers

September 9, 2020

Bio-Path Holdings to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

August 14, 2020

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS

August 13, 2020

Bio-Path Holdings Announces First Patient Dosed in Amended Stage 2 of the Phase 2 Clinical Trial Evaluating Prexigebersen in Acute Myeloid Leukemia

August 10, 2020

Bio-Path Holdings to Announce Second Quarter 2020 Financial Results on August 14, 2020

May 29, 2020

Bio-Path Holdings Presents at 2020 American Society of Clinical Oncology Annual Meeting

May 15, 2020

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

May 13, 2020

Bio-Path Holdings to Present at the 2020 American Society of Clinical Oncology Annual Meeting

May 8, 2020

Bio-Path Holdings to Announce First Quarter 2020 Financial Results on May 15, 2020

April 27, 2020

Bio-Path Holdings Presents at 2020 American Association for Cancer Research Annual Meeting

April 13, 2020

Bio-Path Holdings to Present at the 2020 American Association for Cancer Research Annual Meeting

March 11, 2020

Bio-Path Holdings Appoints Ernst & Young as New Auditor

March 5, 2020

BIO-PATH HOLDINGS REPORTS FULL YEAR 2019 FINANCIAL RESULTS

February 28, 2020

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2019 Financial Results on March 6, 2020

January 8, 2020

Bio-Path Holdings Provides Clinical Update and 2020 Business Outlook

November 26, 2019

BIO-PATH HOLDINGS ANNOUNCES SUCCESSFUL COMPLETION OF SAFETY TESTING IN STAGE 2 OF PHASE 2 CLINICAL TRIAL IN ACUTE MYELOID LEUKEMIA

November 25, 2019

Bio-Path Holdings Announces Closing of $8.0 Million Registered Direct Offering Priced At-the-Market

November 21, 2019

Bio-Path Holdings Announces $8.0 Million Registered Direct Offering Priced At-the-Market

November 21, 2019

BIO-PATH HOLDINGS ANNOUNCES CLEARANCE OF INVESTIGATIONAL NEW DRUG APPLICATION FOR BP1002

November 15, 2019

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS

November 8, 2019

Bio-Path Holdings to Announce Third Quarter 2019 Financial Results on November 15, 2019

October 15, 2019

Bio-Path Holdings Appoints Martina Molsbergen to Board of Directors

September 25, 2019

Bio-Path Updates Intellectual Property Portfolio with Addition of Recently Issued Second Platform Technology Patent

September 3, 2019

Bio-Path Holdings to Present at the H.C. Wainwright 21st Annual Global Investment Conference

August 26, 2019

Bio-Path Announces Patient Dosing in Amended Phase 2 Prexigebersen Acute Myeloid Leukemia Trial

August 15, 2019

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS

August 8, 2019

Bio-Path Holdings to Announce Second Quarter 2019 Financial Results on August 15, 2019

May 16, 2019

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS

May 9, 2019

Bio-Path Holdings to Announce First Quarter 2019 Financial Results on May 16, 2019

April 3, 2019

Bio-Path Holdings Presents Preclinical Data at American Association for Cancer Research Annual Meeting 2019 — Highlighting Important Cancer Gene, STAT3, Therapeutic Strategy in Pancreatic, Non-Small Cell Lung Cancers and Acute Myelogenous Leukemia

March 20, 2019

BIO-PATH HOLDINGS REPORTS FULL YEAR 2018 FINANCIAL RESULTS: Conference Call to be Held Today at 8:30 a.m. ET

March 15, 2019

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2018 Financial Results on March 20, 2019

March 14, 2019

Bio-Bio-Path Holdings, Inc. Announces Closing of $18.5 Million Registered Direct Offering of Common Stock

March 12, 2019

Bio-Path Holdings, Inc. Announces $18.5 Million Registered Direct Offering of Common Stock

March 6, 2019

Bio-Path Announces Clinical Update to Interim Analysis of Phase 2 Prexigebersen Trial in Acute Myeloid Leukemia

February 28, 2019

Bio-Path Holdings to Present Data at the 2019 AACR Annual Meeting

January 23, 2019

Bio-Path Holdings, Inc. Announces Closing of $1.7 Million Registered Direct Offering Priced At-the-Market

January 18, 2019

Bio-Path Holdings, Inc. Announces $1.7 Million Registered Direct Offering Priced At-the-Market

January 18, 2019

Bio-Path Holdings Announces 1-for-20 Reverse Stock Split

January 17, 2019

Bio-Path Holdings, Inc. Announces Closing of Public Offering of Common Stock

January 15, 2019

Bio-Path Holdings, Inc. Announces Pricing of Public Offering of Common Stock (Pricing)

January 15, 2019

Bio-Path Holdings, Inc. Announces Proposed Public Offering of Common Stock (Launch)

December 27, 2018

Bio-Path Holdings Provides Clinical Update and 2019 Business Outlook

December 3, 2018

Bio-Path Holdings Presents Interim Data from Phase 2 Study Evaluating Prexigebersen as a Treatment for Acute Myeloid Leukemia at the 60th Annual American Society of Hematology Annual Meeting

November 15, 2018

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS

November 8, 2018

Bio-Path Holdings to Announce Third Quarter 2018 Financial Results on November 15, 2018

November 1, 2018

Bio-Path Holdings to Present Clinical Data at the 60th Annual American Society of Hematology Annual Meeting

September 25, 2018

Bio-Path Holdings, Inc. Announces Closing of $1.5 Million Registered Direct Offering

September 21, 2018

Bio-Path Holdings, Inc. Announces $1.5 Million Registered Direct Offering

August 29, 2018

Bio-Path Holdings to Present at the H.C. Wainwright 20th Annual Global Investment Conference

August 27, 2018

Bio-Path Holdings Announces First Patient Dosed in Expansion of Phase 2 Trial of Prexigebersen in Acute Myeloid Leukemia

August 16, 2018

Bio-Path Holdings Appoints Dr. Jason B. Fleming to Scientific Advisory Board

August 15, 2018

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS

August 8, 2018

Bio-Path Holdings to Announce Second Quarter 2018 Financial Results on August 15, 2018

May 16, 2018

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

May 10, 2018

Bio-Path Holdings Appoints Dr. Anas Younes to Scientific Advisory Board

May 9, 2018

Bio-Path Holdings to Announce First Quarter 2018 Financial Results on May 16, 2018

April 18, 2018

Pre-Clinical Data Demonstrating Promising Potential of Prexigebersen as Treatment for Solid Tumors in Gynecologic Malignancies Presented at American Association for Cancer Research Annual Meeting

April 3, 2018

Bio-Path Holdings Announces Interim Data from Phase 2 Clinical Trial of Prexigebersen in Combination with Low Dose Cytarabine (LDAC) for the Treatment of Acute Myeloid Leukemia (AML)

April 3, 2018

BIO-PATH HOLDINGS REPORTS FULL YEAR 2017 FINANCIAL RESULT

March 29, 2018

Bio-Path Holdings Announces Publication in The Lancet Haematology

March 27, 2018

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2017 Financial Results on April 3, 2018

March 15, 2018

Bio-Path Holdings to Present Data at the 2018 AACR Annual Meeting

March 6, 2018

Bio-Path Holdings to Present at the 30th Annual ROTH Conference

February 9, 2018

Bio-Path Holdings Announces 1-for-10 Reverse Stock Split

February 5, 2018

Bio-Path Holdings to Present at the BIO CEO & Investor Conference

February 5, 2018

Bio-Path Holdings Appoints Paul Aubert to its Board of Directors

December 29, 2017

Bio-Path Holdings Provides Clinical Update and 2018 Business Outlook

November 9, 2017

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2017 FINANCIAL RESULTS

November 6, 2017

Bio-Path Holdings Highlights Advancements in Preclinical Discovery Efforts

November 3, 2017

Bio-Path Holdings, Inc. Announces $4 Million Registered Direct Offering

November 3, 2017

Bio-Path Holdings to Announce Third Quarter 2017 Financial Results on November 10, 2017

September 5, 2017

Bio-Path Holdings to Present at the Rodman & Renshaw Annual Healthcare Conference

August 10, 2017

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS

August 3, 2017

Bio-Path Holdings to Announce Second Quarter 2017 Financial Results on August 10, 2017

July 19, 2017

Bio-Path Holdings Receives Notice of Allowance for Key U.S. Composition of Matter Patent

July 17, 2017

Bio-Path Holdings Appoints Mark Colonnese to its Board of Directors

June 20, 2017

Stockholder Letter

May 11, 2017

BIO-PATH HOLDINGS REPORTS FIRST QUARTER 2017 FINANCIAL RESULTS

May 4, 2017

Bio-Path Holdings to Announce First Quarter 2017 Financial Results on May 11, 2017

April 17, 2017

Bio-Path Holdings Announces Appointment of Dr. William Hahne as Vice President of Clinical Development

April 5, 2017

Bio-Path Holdings Presents Results Showing Potential of BP1002 as Treatment for Aggressive Non-Hodgkin’s Lymphoma

March 15, 2017

BIO-PATH HOLDINGS REPORTS FULL YEAR 2016 FINANCIAL RESULTS

March 14, 2017

Bio-Path Holdings to Present at the Oppenheimer 27th Annual Healthcare Conference

March 13, 2017

Bio-Path Holdings Announces Rescheduled Date and Time of Full Year 2016 Financial Results on March 15, 2017

March 10, 2017

Bio-Path Holdings to Present Data at the 2017 AACR Annual Meeting

March 9, 2017

Bio-Path Holdings to Announce Fourth Quarter and Full Year 2016 Financial Results on March 14, 2017

February 21, 2017

Bio-Path Holdings Appoints Dr. Craig Hooper to Scientific Advisory Board

February 7, 2017

Bio-Path Holdings to Present at the 19th Annual BIO CEO & Investor Conference

December 6, 2016

Bio-Path Holdings Presents Clinical Data Evaluating BP1001 as a Treatment for Chronic Myelogenous Leukemia at the 58th Annual American Society of Hematology Annual Meeting

November 10, 2016

BIO-PATH HOLDINGS REPORTS THIRD QUARTER 2016 FINANCIAL RESULTS

November 4, 2016

BIO-PATH HOLDINGS TO ANNOUNCE THIRD QUARTER 2016 FINANCIAL RESULTS ON NOVEMBER 10, 2016

November 4, 2016

Bio-Path Holdings to Present Data at the 2016 ASH Annual Meeting

November 3, 2016

Bio-Path Announces Orphan Drug Designation in the European Union for BP1001 for the Treatment of Acute Myeloid Leukemia

November 2, 2016

Bio-Path Holdings Announces First Patient Dosed in Phase 2 Trial Evaluating BP1001 in Acute Myeloid Leukemia

September 6, 2016

Bio-Path Holdings to Present at the Rodman & Renshaw 18th Annual Global Investment Conference

August 10, 2016

BIO-PATH HOLDINGS REPORTS SECOND QUARTER 2016 FINANCIAL RESULTS

August 3, 2016

BIO-PATH HOLDINGS TO ANNOUNCE SECOND QUARTER 2016 FINANCIAL RESULTS ON AUGUST 10, 2016

July 6, 2016

Bio-Path Holdings to Present at the 2nd Annual Cantor Fitzgerald Healthcare Conference

June 29, 2016

Bio-Path Holdings, Inc. Announces $10 Million Registered Direct Offering

June 28, 2016

Bio-Path Holdings Announces Collaboration With Thomas Jefferson University for Systemic Antisense Immunotherapy Treatment for Brain Cancer

June 20, 2016

Bio-Path Holdings to Join Russell 3000® and Global Indexes

June 6, 2016

Bio -Path Holdings Reports Promising Data from Phase I and Phase II Clinical Trials of BP1001 in Blood Cancers Presented at ASCO 2016

May 19, 2016

Bio-Path Holdings to Present Data at 2016 American Society of Clinical Oncology Annual Meeting

May 11, 2016

Bio-Path Holdings Reports First Quarter 2016 Financial Results

May 5, 2016

Bio-Path Holdings to Present at 18th Annual TIDES: Oligonucleotide and Peptides Therapeutic Conference

May 4, 2016

Bio-Path Holdings to Announce First Quarter 2016 Financial Results on May 11, 2016

March 23, 2016

Bio-Path Holdings Announces Research Collaboration on Autoimmune Indication with The University of Texas Southwestern Medical Center

March 15, 2016

Bio-Path Holdings Reports Fiscal Year 2015 Operational and Financial Results

March 8, 2016

Bio-Path Holdings Announces Pancreatic Cancer Research Collaboration with Leading Oncology Institution

March 7, 2016

Bio-Path Holdings to Present at the 28th Annual ROTH Conference on Monday, March 14 at 4:30 p.m. Pacific Time (7:30 p.m. Eastern Time)

March 3, 2016

Bio-Path Holdings Announces Completion of the Safety Segment of the Phase II Clinical Trial of BP1001 in Acute Myeloid Leukemia

January 6, 2016

Bio-Path Holdings to Present at Biotech Showcase™ 2016

December 8, 2015

Bio-Path Holdings’ Data from Phase I and Safety Segment of Phase II Clinical Trials in Blood Cancers Presented at 57th American Society of Hematology (ASH) Annual Meeting

November 10, 2015

Bio-Path Holdings Reports Third Quarter 2015 Operational and Financial Results

November 5, 2015

Bio-Path Holdings’ Data to be Presented at 57th American Society of Hematology (ASH) Annual Meeting

October 13, 2015

Bio-Path Holdings to Present at the 14th Annual BIO Investor Forum

October 9, 2015

Bio-Path Holdings Announces Successful Completion of Cohort 7 of Phase Ib of Clinical Trial Evaluating Liposomal Grb-2 in Acute Myeloid Leukemia

September 2, 2015

Bio-Path Holdings To Present at the 17th Annual Rodman & Renshaw Global Investment Conference

August 31, 2015

Bio-Path Holdings Forms Scientific Advisory Board to Support Advancement of Liposomal Grb-2 in Blood Cancers

August 11, 2015

Bio-Path Holdings Reports Second Quarter 2015 Operational and Financial Results

June 25, 2015

Bio-Path Holdings Announces “At the Market” Offering with Cantor Fitzgerald

May 12, 2015

Bio-Path Holdings Reports First Quarter 2015 Operational and Financial Results

April 28, 2015

Bio-Path Holdings Granted Orphan Drug Designation for Liposomal Grb-2 in Acute Myeloid Leukemia

April 24, 2015

Letter to Shareholder from President and CEO

April 22, 2015

Bio-Path Holdings’ Drug Delivery Technology to be Featured in a Presentation at IBC’s 17th Annual TIDES Oligoneucleotide and Peptide Therapeutics Conference

March 17, 2015

Bio-Path Holdings Reports Fiscal Year 2014 Operational and Financial Results

March 5, 2015

Letter to Shareholder from President and CEO

February 9, 2015

Bio-Path Holdings Starts Phase II Study with Liposomal Grb-2 in AML Patients

January 7, 2015

Bio-Path Holdings’ Liposomal Grb-2 Featured in Peer-Reviewed Journal “Expert Opinion on Drug Delivery”

January 6, 2015

Bio-Path Holdings to Present at the Biotech Showcase 2015 Conference in San Francisco, CA on Tuesday, January 13, 2015 at 3:30 p.m. Pacific Time

December 22, 2014

Bio-Path Holdings to Initiate Development of Liposomal Bcl-2 in Follicular Lymphoma – Company Broadening its Pipeline with Second Product Candidate –

November 17, 2014

Bio-Path Holdings Reports Third Quarter 2014 Operational and Financial Results

November 6, 2014

Bio-Path Holdings Appoints Amy P. Sing, M.D. to its Board of Directors

October 16, 2014

NASDAQ Release: Bio-Path Holdings, Inc. to Ring The NASDAQ Stock Market Closing Bell (Friday, October 17, 2014 at 3:45 – 4:00 PM Eastern Time)

October 7, 2014

Bio-Path Holdings Successfully Completes Cohort 6 of Phase I Clinical Trial Evaluating Liposomal Grb-2 in Blood Cancers

September 30, 2014

Bio-Path Holdings to Present at the 13th Annual BIO Investor Forum in San Francisco on Tuesday October 7, 2014 at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time)

August 18, 2014

Bio-Path Holdings Reports Second Quarter 2014 Operational and Financial Results

June 30, 2014

Bio-Path Holdings Added to Russell Global, Russell 3000 and Russell Microcap Indexes

June 19, 2014

Enrollment Continues Into Bio-Path Holdings Phase I Clinical Trial

May 19, 2014

Bio-Path Holdings Reports First Quarter 2014 Operational and Financial Results

April 1, 2014

Bio-Path Holdings Reports Fiscal Year 2013 Operational and Financial Results

March 26, 2014

Bio-Path Holdings, Inc. Appoints Ulrich M. Mueller Chief Operating Officer

March 5, 2014

Bio-Path Holdings Announces Uplisting to the NASDAQ Capital Market

January 16, 2014

Bio-Path Holdings, Inc. to Raise $10 Million in Registered Direct Offering

January 7, 2014

Bio-Path Holdings to Present at the Biotech Showcase 2014 Conference in San Francisco, CA on Wednesday, January 15, 2014 at 8:00 a.m. Pacific Time

December 9, 2013

Preliminary Results from Bio-Path Holdings’ Phase I Clinical Trial Presented at the Annual Meeting of the American Society of Hematology (ASH) in New Orleans

November 15, 2013

Bio-Path Holdings Reports Third Quarter 2013 Operational and Financial Results

November 7, 2013

Data from Bio-Path Holdings Phase I Clinical Trial in Hematological Cancers to be Presented at American Society of Hematology Annual Meeting: Data Suggests Potential for AML and MDS Disease Inhibition with Liposomal Grb-2-

October 1, 2013

Bio-Path Holdings to Present at the 12th Annual BIO Investor Forum

September 19, 2013

Bio-Path Holdings, Inc. Retains Investment Banking Firm Maxim Group LLC

August 15, 2013

Bio-Path Holdings Reports Second Quarter 2013 Operational and Financial Results

August 9, 2013

Bio-Path Holdings’ Liposomal Delivery Technology Achieves Major Milestone in development of Antisense Therapeutics

July 22, 2013

Bio-Path Holdings Initiates Development of Liposomal Grb-2 for Triple Negative and Inflammatory Breast Cancers

June 6, 2013

Bio-Path Holdings Successfully Completes Fifty Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

May 16, 2013

Bio-Path Holdings Reports First Quarter 2013 Operational and Financial Results

April 2, 2013

Bio-Path Holdings Reports Fiscal Year 2012 Operational and Financial Results

March 7, 2013

Bio-Path Holdings Begins Enrollment in Fifth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias

January 3, 2013

Bio-Path Holdings to Present at Biotech Showcase 2013 Conference in San Francisco, California on Tuesday, January 8, 2013 at 11:00 am Pacific Time

December 6, 2012

Bio-Path Holdings to Expand Development of Liposomal Grb-2 into two additional indications: Triple Negative and Inflammatory Breast Cancers

November 16, 2012

Bio-Path Holdings Reports Third Quarter 2012 Operational and Financial Results

November 14, 2012

Bio-Path Holdings Successfully Completes Fourth Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

October 4, 2012

Bio-Path Holdings Adds New Board Member

October 3, 2012

Bio-Path Holdings to Present at the 11th Annual Bio Investor Forum Conference in San Francisco on Wednesday Oct 10, 2012 at 11:30 am Pacific Time (2:30 pm Eastern Time)

September 4, 2012

Bio-Path Holdings to Present at the Rodman & Renshaw Annual Global Investment Conference

August 16, 2012

Bio-Path Holdings Reports Second Quarter 2012 Operational and Financial Results

July 25, 2012

Bio-Path Holdings Begins Enrollment in Fourth Cohort of Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemias

June 4, 2012

Bio-Path Holdings Shares Commence Trading On OTCQX, The Top Tier Of The OTC Market

May 29, 2012

Bio-Path Holdings Successfully Completes Third Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

May 17, 2012

Bio-Path Holdings Reports First Quarter 2012 Operational and Financial Results – Quarter Highlighted by Progress with Lead Product Candidate, Liposomal Grb-2

April 3, 2012

Bio-Path Holdings Reports Fiscal Year 2011 Operational and Financial Results

March 29, 2012

Bio-Path Holdings Engages PondelWilkinson for Retailer Investor Relations Program

February 7, 2012

Bio-Path Holdings Successfully Completes Second Cohort in Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

January 4, 2012

Bio-Path Holdings to Present at Biotech Showcase 2012 Conference

December 13, 2011

Bio-Path Holdings’ Initial Phase I Data in Leukemia Clinical Trial Demonstrates that Its Neutral Lipid Delivery Technology Antisense Drug BP-101-100-1.01 (Liposomal Grb-2) Is Well Tolerated with Activity Seen at Low-Starting Dose

November 15, 2011

Press Release Form 8-K – 3rd Quarter Financial Results

October 24, 2011

Proxy Statement fothereer 2011

October 19, 2011

Bio-Path Holdings to Present at the 10th Annual BIO Investors Forum Conference in San Francisco on Wednesday, October 26, 2011. Link to Conference at 3:00pm Pacific Time

October 4, 2011

Initial Data from Bio-Path Holdings’ Phase I Clinical Trial Accepted for Presentation at American Society ofHematology Annual Meeting

September 6, 2011

Bio-Path Holdings to Present at the Rodman & RenshawAnnual Global Investment Conference

August 11, 2011

First Cohort Successfully Completed in Bio-Path Holding’s Phase I Clinical Trial of Lead Product Candidate Liposomal Grb-2 in Leukemia

July 27, 2011

Bio-Path recently featured in Genomeweb/Gene Silencing News

May 17, 2011

Bio-Path Holdings Reports First Quarter 2011 Financial Results

April 28, 2011

Bio-Path Holdings Appoints Dr. Ana M. Tari Director, Preclinical Operations and Research

April 4, 2011

Zack’s Small-Cap Research Release

March 31, 2011

Bio-Path Holdings Reports Fiscal Year 2010 Operation and Financial Results

February 23, 2011

Zack’s Small-Cap Research Release

February 23, 2011

CEOCFO Interviews Peter H. Nielsen, CEO

November 15, 2010

Bio-Path Holdings Reports Third Quarter 2010 Financial Results

November 3, 2010

Bio-Path Holdings Awarded Grant From The U.S. Government’s Qualifying Therapeutic Discovery Project Program

August 17, 2010

Bio-Path Holdings Reports Fiscal 2010 Second Quarter Financial Results Company Also Completes Initial Sale of Registered Shares Under Financing With Lincoln Park Capital

July 29, 2010

Bio-Path Holdings announces Dosing of First Patient in a Phase I Clinical Trial of its Liposomal Grb-2 Cancer Drug Candidate

June 4, 2010

Bio-Path Holdings Signs Equity Financing Deal Equity Purchase Agreement With Institutional Investor Lincoln Park Capital to Provide Up to $7 Million In New Capital

March 12, 2010

FDA Allows IND For Bio-Path Holdings’ Liposomal Grb-2 Company to Commence Phase I Clinical Trial Of Its Cancer Drug To Treat CML, AML, ALL, & MDS

December 14, 2009

Bio-Path Holdings, Inc. Completes Private Placement Capital Raise and Provides Update to IND Status

November 2, 2009

Bio-Path Holdings, Inc. Operations Update

September 22, 2009

Bio-Path Holdings, Inc. Announces Plans To Develop Liposome Tumor Targeting Technology Licensed from The University of Texas M. D. Anderson Cancer Center

July 23, 2009

Bio-Path Holdings, Inc. Provides Operations Update and Overview Of New Targeting Technology

June 6, 2009

Proxy

June 6, 2009

Proxy Statement

April 14, 2009

Bio-Path Holdings, Inc. Announces Clinical Support Agreement With ACORN And Names Bradley G. Somer, M.D., As Medical Officer For Phase I Clinical Trial

December 10, 2008

Letter To Shareholders

December 3, 2008

Bio-Path Holdings, Inc. Retains Alliance Advisors, LLC to Implement Investor Relations Program

November 17, 2008

Bio-Path Holdings, Inc. Announces the Signing of a Drug Manufacturing Agreement with Althea Technologies, Inc.

March 3, 2008

Bio-Path Becomes a Publicly Traded Company

Bio-Path Holdings

All Rights Reserved

Office:

4710 Bellaire Blvd, Suite 210
Bellaire, TX 77401

T: (832) 742-1357

R&D:

5455 Dashwood Street, Suite 300
Bellaire, TX 77401

T: (832) 742-1357

logo
  • About Bio-Path
    • Overview
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
    • Partnering Opportunities
  • Technology
  • Pipeline
    • Pipeline
    • Prexigebersen
    • BP1001-A
    • BP1002
    • BP1003
  • Patients
  • Investors
    • Overview
    • SEC Filings
    • Corporate Governance
  • Media
    • Press Releases
    • Events
    • Presentations & Publications
  • Careers
  • Contact Us